MX2019002479A - Nnif y péptidos relacionados con nnif y métodos relacionados. - Google Patents

Nnif y péptidos relacionados con nnif y métodos relacionados.

Info

Publication number
MX2019002479A
MX2019002479A MX2019002479A MX2019002479A MX2019002479A MX 2019002479 A MX2019002479 A MX 2019002479A MX 2019002479 A MX2019002479 A MX 2019002479A MX 2019002479 A MX2019002479 A MX 2019002479A MX 2019002479 A MX2019002479 A MX 2019002479A
Authority
MX
Mexico
Prior art keywords
nnif
methods
cancer
peptides
patients
Prior art date
Application number
MX2019002479A
Other languages
English (en)
Inventor
Con Yost Christian
A Zimmerman Guy
S Weyrich Andrew
Schiffman Joshua
Original Assignee
The Univ Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Utah Research Foundation filed Critical The Univ Of Utah Research Foundation
Publication of MX2019002479A publication Critical patent/MX2019002479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proveen el factor de inhibición de NET neonatal (nNIF) y péptidos relacionados con nNIF (NRP). Asimismo, se proveen métodos para tratamiento y profilaxis para trastornos inflamatorios y cáncer. Además, se proveen métodos para la inhibición de metástasis en pacientes que padecen cáncer. Los métodos pueden incluir la administración de nNIF y/o un NRP a pacientes que padecen un trastorno inflamatorio o un cáncer o que están en riesgo de padecerlos.
MX2019002479A 2016-09-02 2017-09-05 Nnif y péptidos relacionados con nnif y métodos relacionados. MX2019002479A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US201762492019P 2017-04-28 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (1)

Publication Number Publication Date
MX2019002479A true MX2019002479A (es) 2019-09-19

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002479A MX2019002479A (es) 2016-09-02 2017-09-05 Nnif y péptidos relacionados con nnif y métodos relacionados.

Country Status (13)

Country Link
US (1) US10857201B2 (es)
EP (1) EP3506924A4 (es)
JP (1) JP2019534247A (es)
KR (1) KR20190045271A (es)
CN (1) CN109937047A (es)
AU (1) AU2017321965A1 (es)
BR (1) BR112019004299A2 (es)
CA (1) CA3035770A1 (es)
MX (1) MX2019002479A (es)
RU (1) RU2019109049A (es)
SG (1) SG11201901830UA (es)
WO (1) WO2018045371A2 (es)
ZA (1) ZA201901942B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146237A1 (en) * 2020-05-04 2023-03-15 University of Utah Immunothrombosis in covid-19 acute respiratory distress syndrome
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP4219534A3 (en) * 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Also Published As

Publication number Publication date
CN109937047A (zh) 2019-06-25
RU2019109049A3 (es) 2020-12-24
US10857201B2 (en) 2020-12-08
EP3506924A4 (en) 2020-05-20
EP3506924A2 (en) 2019-07-10
US20190201487A1 (en) 2019-07-04
WO2018045371A2 (en) 2018-03-08
WO2018045371A3 (en) 2018-04-12
RU2019109049A (ru) 2020-10-05
CA3035770A1 (en) 2018-03-08
BR112019004299A2 (pt) 2019-05-28
JP2019534247A (ja) 2019-11-28
AU2017321965A1 (en) 2019-04-04
SG11201901830UA (en) 2019-03-28
KR20190045271A (ko) 2019-05-02
ZA201901942B (en) 2020-10-28

Similar Documents

Publication Publication Date Title
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
MX2017003565A (es) Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
GEP20217317B (en) Combination therapy for the treatment of cancer
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
TW201613636A (en) Methods of treating Alzheimer's Disease
EA201791736A1 (ru) Комбинированная терапия для лечения рака
IL282007A (en) Medicine to treat chronic cough
MX2019003235A (es) Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MX2019002479A (es) Nnif y péptidos relacionados con nnif y métodos relacionados.
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
MX2017016346A (es) Metodos de tratamiento con taselisib.
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease